ALEXANDRIA, Va., Feb. 4 /PRNewswire/ -- Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.
“We are pleased to work with Oxford which provided EUSA Pharma with the financial means to leverage its outstanding transatlantic commercial infrastructure,” said Bryan Morton, president and chief executive officer of EUSA Pharma.
About Oxford Finance Corporation
About EUSA Pharma
Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company’s established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus. For more information please visit www.eusapharma.com.
CONTACT: Shelly Davis, Oxford Finance Corporation, +1-703-519-6013,
sdavis@oxfordfinance.com; or Bryan Morton, President & Chief Executive
Officer, EUSA Pharma, +44(0)1865-784255, bryan.morton@eusapharma.com
Web site: http://www.oxfordfinance.com/
